Wave Life Sciences (WVE, $7.99) posts disappointing trial results from anti-Huntington disease drug
Biotech company Wave Life Sciences’ shares plummeted , after clinical test results on a anti-Huntington disease drug turned out to be a bit disappointing.
The trial, which compared the results from oligonucleotide therapeutic WVE-120102 with a placebo, showed a statistically significant 12.4% reduction in a disease-causing mutant huntingtin protein, at the highest doses tested ( as indicated in the Wave Life’s statement). However, “there was no difference" in total huntingtin protein compared with placebo, the company said.
The drug was generally safe and “well tolerated among patients receiving doses up to 16 mg in both single and multidose portions of the study,” according to Wave Life.
Wave Life conducted a Phase 1b/2a Precision-HD2 trial. Results from another Phase 1b/2a, Precision-HD1( evaluating WVE-120101 in early manifest Huntington patients) is expected to come out in the second half of next year, as indicated by the company.
Huntington disease often appears in adults in their 30s and 40s, is a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability, according to the National Institutes of Health.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
WVE in -3.35% downward trend, falling for three consecutive days on October 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where WVE declined for three days, in 249 of 289 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for WVE entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for WVE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where WVE advanced for three days, in 209 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
WVE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.595) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (12.953) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. WVE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of nucleic acid therapeutics
Industry Biotechnology
Advertisement